UM researchers have developed a deep learning model to predict compound protein interactions. GraphBAN is an inductive ...

Despite issues with data quality and privacy, the use of AI in drug discovery has enormous potential to revolutionize the pharmaceutical sector by providing quicker, more accurate, and more ...

Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter "Elix"), an AI drug discovery company with the mission of "Rethinking Drug Discovery", today announced that it has entered into a drug discovery ...

Strategic Partnership Aims to Create a Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with an AI Drug Discovery Platform TOKYO, April 15, 2025--(BUSINESS ...

PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced ...

Elix Inc. has entered into a drug discovery collaboration with Prism Biolab Co. Ltd. to accelerate AI-driven drug discovery for challenging protein-protein interaction targets. The partnership will ...

Advancements in the drug discovery process are undergoing a profound transformation, with novel technologies like organoids, nanotechnology, AI, and organs-on-a-chip models playing an important role.

Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform This partnership will accelerate ...

Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform This partnership will accelerate research ...

Interested in finding a better way to develop drugs to treat amyotrophic lateral sclerosis (ALS), Northeastern researcher ...